LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2019-02-20
Target enrollment:
Participant gender:
Summary
Patients with metastatic breast cancer receiving at least one single agent chemotherapy and
demonstrating stable disease or disease progression at two consecutive clinical/radiological
assessments (at an interval of at least 2 weeks).
Transforming growth factor-beta (TGFΒ) blockade will enhance response of irradiated tumors
and improve the function of Dendritic and T cells. Patients will receive 300 mg/day of study
drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day
cycle). Radiation to a metastatic site will be delivered at a dose of 7.5 Gy, given
consecutively on days 1-3-5.